Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today long-term data from the pivotal Phase 1/2 MajesTEC-1 study showing...

Related Keywords

Amsterdam ,Noord Holland ,Netherlands ,Chicago ,Illinois ,United States ,American ,Rachel Kobos ,Satu Glawe ,Christie Corbett ,Eastern Cooperative Oncology Group ,Exchange Commission ,None Of The Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,European Medicines Agency ,Janssen Pharmaceutical Companies ,European Commission ,American Cancer Society ,American Society Of Clinical Oncology ,National Comprehensive Cancer Network ,Janssen Research Development ,Companies Of Johnson ,International Myeloma Working Group ,Janssen Oncology Research Development ,Other Administration Reactions ,Johnson ,National Cancer Institute ,Clinical Oncology ,Annual Meeting ,Confidence Interval ,Not Evaluable ,Amsterdam University Medical Centers ,Suggest Durable Responses ,Biweekly Dosing ,Vice President ,Janssen Oncology Research ,Prophylactic Tocilizumab ,Cytokine Release Syndrome ,Lee Criteria ,Independent Review Committee ,Drug Administration ,National Comprehensive Cancer ,Risk Evaluation ,Mitigation Strategy ,Release Syndrome ,Fetal Toxicity ,Prescribing Information ,Boxed Warning ,Pharmaceutical Companies ,Infectious Diseases ,Janssen Research ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Long Term Follow Up From ,Patients With ,Refractory Multiple ,American Society ,Responses With Biweekly Dosing ,Refractory Multiple Myeloma Achieving ,Clinical Response ,Participants With Relapsed ,Refractory Multiple Myeloma ,Accessed June ,Escalation Study ,Clinical Practice Guidelines ,Comprehensive Cancer ,Plasma Cell ,Statistics About Multiple Myeloma ,Janssen Oncology ,